Table 1.
Baseline characteristics of patients diagnosed with localized breast cancer at age 50 years or older who received adjuvant hormonal therapy
| Categories | All patients (n = 4226) | AI-brand (n = 2815) | AI-generic (n = 1411) |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| Type of therapy | |||
| AI-brand | 2815 (66.6) | 2815 (100.0) | |
| AI-generic | 1411 (33.4) | 1411 (100.0) | |
| HT start year* | |||
| 2007 | 698 (16.5) | 698 (24.8) | 0 (0) |
| 2008 | 1002 (23.7) | 1002 (35.6) | 0 (0) |
| 2009 | 787 (18.6) | 787 (28.0) | 0 (0) |
| 2010 | 1007 (23.8) | 309 (11.0) | 698 (49.5) |
| 2011 | 732 (17.3) | 19 (0.7) | 713 (50.5) |
| Start year | |||
| Pregeneric | 2110 (50.0) | 2110 (75.0) | 0 (0) |
| Postgeneric | 2116 (50.0) | 705 (25.0) | 1411 (100.0) |
| Prescription coverage Characteristics | |||
| Adjusted 30-day copay* | |||
| <$15 | 1666 (39.4) | 458 (16.3) | 1208 (85.6) |
| $15-$30 | 1350 (32.0) | 1167 (41.5) | 183 (13.0) |
| >$30 | 1210 (28.6) | 1190 (42.3) | 20 (1.4) |
| Pharmacy deductible type | |||
| No deductible | 2390 (85.1) | 1641 (85.3) | 749 (84.6) |
| Pharmacy deductible only | 234 (8.3) | 161 (8.4) | 73 (8.3) |
| Shared pharmacy/medical | 185 (6.6) | 122 (6.3) | 63 (7.1) |
| Coverage type* | |||
| Commercial | 3739 (88.5) | 2541 (90.3) | 1198 (84.9) |
| Medicare | 487 (11.5) | 274 (9.7) | 213 (15.1) |
| Clinical characteristics | |||
| Provider specialty* | |||
| Primary care/other | 1076 (25.5) | 742 (26.4) | 334 (23.7) |
| Hematology/oncology | 3150 (74.5) | 2073 (73.6) | 1077 (76.3) |
| Surgery* | |||
| Lumpectomy/other | 1946 (46.1) | 1245 (44.2) | 701 (49.7) |
| Mastectomy | 2280 (53.9) | 1570 (55.8 | 710 (50.3) |
| Comorbidities | |||
| 1–5 | 3390 (80.2) | 2243 (79.7) | 1147 (81.3) |
| 6 + | 836 (19.8) | 572 (20.3) | 264 (18.7) |
| Age at diagnosis, y* | |||
| 50–55 | 719 (17.0) | 487 (17.3) | 232 (16.4) |
| 56–65 | 2379 (56.3) | 1612 (57.3) | 767 (54.4) |
| 66–75 | 728 (17.2) | 445 (15.8) | 283 (20.1) |
| 75+ | 400 (9.5) | 271 (9.6) | 129 (9.1) |
| Sociodemographic characteristics | |||
| Race/ethnicity | |||
| White | 2530 (59.9) | 1699 (60.4) | 831 (58.9) |
| Black | 312 (7.4) | 207 (7.4) | 105 (7.4) |
| Hispanic | 217 (5.1) | 145 (5.2) | 72 (5.1) |
| Asian | 75 (1.8) | 49 (1.7) | 26 (1.8) |
| Other/unknown race | 1092 (25.8) | 715 (25.4) | 377 (26.7) |
| Education* | |||
| High school or less | 922 (21.8) | 639 (22.7) | 283 (20.1) |
| More than high school | 3034 (78.2) | 2176 (77.3) | 1128 (79.9) |
| Household income* | |||
| Low (<$40000) | 701 (15.6) | 508 (18.1) | 193 (13.7) |
| Middle ($40K-$100K) | 1835 (43.4) | 1189 (42.2) | 646 (45.8) |
| High (>$100K) | 674 (17.4) | 447 (15.9) | 227 (16.1) |
| Unknown | 1016 (23.7) | 671 (23.8) | 345 (24.5) |
| Region | |||
| Northeast | 744 (17.6) | 476 (16.9) | 268 (19.0) |
| West | 891 (21.1) | 582 (20.7) | 296 (21.0) |
| Midwest | 1699 (40.2) | 595 (21.2) | 541 (38.3) |
| South | 888 (21.0) | 1158 (41.2) | 306 (21.7) |
* Two-sided X 2 for all comparisons, P < .01. AI-brand = brand name aromatase inhibitor; AI-generic = generic aromatase inhibitor.